Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.3420
+0.00972.92%
Pre-market: 0.3379-0.0041-1.20%07:10 EDT
Volume:2.00M
Turnover:679.73K
Market Cap:6.46M
PE:-0.09
High:0.3609
Open:0.3321
Low:0.3229
Close:0.3323
52wk High:14.80
52wk Low:0.3229
Shares:18.90M
Float Shares:17.23M
Volume Ratio:1.14
T/O Rate:11.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.20
PE(LYR):-0.08

Loading ...

VolitionRx shareholders approved reverse stock split authorization at special meeting

Reuters
·
Apr 02

VolitionRx publishes corporate presentation outlining Nu.Q licensing-led cancer and sepsis diagnostics strategy

Reuters
·
Apr 01

VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate

Benzinga Earnings
·
Apr 01

VolitionRx FY25 net loss narrows 14%; revenue rises 40% to $1.7 million

Reuters
·
Apr 01

Press Release: VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Dow Jones
·
Apr 01

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

VolitionRX Ltd - Secures €2.0 Mln Non-Dilutive Funding From Belgian Regional Agencies

THOMSON REUTERS
·
Mar 31

Press Release: VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Dow Jones
·
Mar 31

VolitionRx study shows Nu.Q nucleosome biomarkers elevated in trauma patients, linked to VTE

Reuters
·
Mar 30

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

VolitionRx announces ELCC abstract on Nu.Q lung cancer blood test; study links preoperative H3K27Me3-nucleosome levels to recurrence-free and overall survival risk stratification

Reuters
·
Mar 26

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

THOMSON REUTERS
·
Mar 26

VolitionRx schedules FY2025 earnings conference call; business update webcast opens to investors

Reuters
·
Mar 26

VolitionRx reports Capture-Seq blinded validation sensitivity rises to 93%; specificity climbs to 95%

Reuters
·
Mar 25

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 19

BRIEF-Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna

Reuters
·
Mar 18

VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives

Reuters
·
Mar 18

Volition Reports Breakthrough in Liquid Biopsy: Achievement of Over 99% Purity in Isolating Cancer DNA

THOMSON REUTERS
·
Mar 18